Xeris Biopharma Holdings (XERS) Net Margin (2020 - 2026)
Xeris Biopharma Holdings (XERS) posted Net Margin of 2.69% for Q1 2026, down 79.19% on a QoQ basis from 12.91% in Q4 2025, and up 1802.0% year-over-year from 0.14% in Q1 2025.
Xeris Biopharma Holdings (XERS) Net Margin (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings' Net Margin history runs 7 years deep, the most recent figure standing at 2.69% for Q1 2026.
- Quarterly Net Margin rose 1802.0% year-over-year to 2.69% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3.81% (up 2407.0% YoY) and the FY2025 annual result came in at 0.19%, up 2719.0% from the prior year.
- Net Margin was 2.69% for Q1 2026 at Xeris Biopharma Holdings, down from 12.91% in the prior quarter.
- Across five years, Net Margin topped out at 12.91% in Q4 2025 and bottomed at 152.74% in Q1 2022.
- A 5-year average of 37.88% and a median of 30.16% in 2023 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2022 — Net Margin surged 20548 bps — and 2024, when it plunged 377 bps.
- Xeris Biopharma Holdings' Net Margin stood at 39.01% in 2022, then advanced by 23 bps to 30.16% in 2023, then soared by 72 bps to 8.51% in 2024, then soared by 252 bps to 12.91% in 2025, then plunged by 79 bps to 2.69% in 2026.
- Business Quant data shows XERS's Net Margin at 2.69% in Q1 2026, 12.91% in Q4 2025, and 0.83% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 9.29% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 26.57% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -33.66% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 35.18% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 5.03% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 24.30% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 4.16% |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 2.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.69% |
| Dec 31, 2025 | 12.91% |
| Sep 30, 2025 | 0.83% |
| Jun 30, 2025 | -2.70% |
| Mar 31, 2025 | -15.34% |
| Dec 31, 2024 | -8.51% |
| Sep 30, 2024 | -29.00% |
| Jun 30, 2024 | -31.22% |
| Mar 31, 2024 | -46.71% |
| Dec 31, 2023 | -30.16% |
| Sep 30, 2023 | -25.23% |
| Jun 30, 2023 | -52.20% |
| Mar 31, 2023 | -50.71% |
| Dec 31, 2022 | -39.01% |
| Sep 30, 2022 | -73.44% |
| Jun 30, 2022 | -103.47% |
| Mar 31, 2022 | -152.74% |
| Dec 31, 2021 | -237.02% |
| Sep 30, 2021 | -235.16% |
| Jun 30, 2021 | -308.95% |